Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults

NCT06334393 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Zika
Zika Virus Infection

Interventions

BIOLOGICAL: VLA1601
BIOLOGICAL: CpG 1018®
BIOLOGICAL: 3M-052-AF

Sponsor

Valneva Austria GmbH